This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dorr, R. T. Articles by Osborne, C. K. Search for Related Content PubMed PubMed Citation Articles by Dorr, R. T. Articles by Osborne, C. K.

Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine¹

University of Arizona, Colleges of Medicine and Pharmacy, Cancer Center, Tucson, Arizona 85724 [R.T.D., J.D.L., M.S.] and the Department of Medicine, University of Texas, Health Sciences Center at San Antonio, San Antonio, Texas [D.D.V.H., C.K.O.]

The lipophilic antitumor alkaloid acronycine (ACRO) was solubilized in the cosolvent system used for etoposide. ACRO in this etoposide diluent (VPD) was found to be cytotoxic (50% colony formation in soft agar) in fresh human tumors from patients with renal cell cancer, ovarian cancer, uterine cancer, and metastatic tumors of unknown primary. In P-glycoprotein-positive, multidrug-resistant (MDR) cell lines, ACRO in VPD was active in MDR Chinese hamster ovary cells but not against MDR L1210 murine leukemia cells, 8226 human myeloma cells, or human CCRF-CEM lymphoblasts. In mice, ACRO in VPD was active in two solid tumor models and an i.p. MOPC-315 plasmacytoma model. ACRO i.p. in 10% VPD (v/v%) produced significant tumor growth delays in (a) nude mice bearing human MCF-7 breast cancer xenografts and (b) C57BL mice bearing colon 38 tumor. In MOPC-315-bearing mice, a single i.p. ACRO dose of 25 mg/kg was as effective as melphalan (15 mg/kg) at prolonging life span. Finally, ACRO pharmacokinetics was evaluated in mice given single 25-mg/kg doses i.p. or p.o. The oral bioavailability of an ACRO solution in VPD was only 50% but both i.p. and p.o. regimens achieved plasma levels >1.0 µg/ml. The plasma half-life was just under 2 h. These results show that parenteral ACRO in VPD comprises a cytotoxic antitumor agent with improved bioavailability over p.o. administration. ACRO is active in vitro against several human solid tumors but is cross-resistant in 3 of 4 MDR tumor cell lines. The prior clinical activity of p.o. ACRO in myeloma and the new results in MOPC-315 plasmacytomas in mice suggest that ACRO in VPD could have activity against human multiple myeloma.

¹ Supported in part by Grant CA 17094 from the National Cancer Institute, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ 85724.

Received 8/31/87. Revised 8/ 8/88. Revised 10/13/88. Accepted 10/20/88.

This article has been cited by other articles:

				S. Leonce, V. Perez, S. Lambel, D. Peyroulan, F. Tillequin, S. Michel, M. Koch, B. Pfeiffer, G. Atassi, J. A Hickman, et al. Induction of Cyclin E and Inhibition of DNA Synthesis by the Novel Acronycine Derivative S23906-1 Precede the Irreversible Arrest of Tumor Cells in S Phase Leading to Apoptosis Mol. Pharmacol., December 1, 2001; 60(6): 1383 - 1391. [Abstract] [Full Text] [PDF]

				N. Guilbaud, L. Kraus-Berthier, F. Meyer-Losic, V. Malivet, C. Chacun, M. Jan, F. Tillequin, S. Michel, M. Koch, B. Pfeiffer, et al. Marked Antitumor Activity of a New Potent Acronycine Derivative in Orthotopic Models of Human Solid Tumors Clin. Cancer Res., August 1, 2001; 7(8): 2573 - 2580. [Abstract] [Full Text] [PDF]